Serological Marker Panel for Crohn's Disease Recurrence Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting post-operative recurrence of Crohn's disease are burdensome for patients and provide conflicting data regarding the efficacy of clinical, serological, and histological features for recurrence prediction.
Innovation Solution
A method involving the detection of specific serological markers such as anti-flagellin antibodies, pANCA, and clinical markers like active smoking to calculate a risk score for predicting post-operative recurrence of Crohn's disease, utilizing pre-operative samples to identify patients at risk for endoscopic, histological, or clinical recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If endoscopy, radiographic or histological techniques are used to detect recurrence, then recurrence detection accuracy is improved, but patient burden increases
Solution Approach 1:
The patent applies preliminary action by measuring serological markers (ASCAs, anti-flagellin antibodies, pANCA) in pre-operative samples to predict post-operative recurrence risk before the actual recurrence occurs. This allows clinicians to identify high-risk patients upfront and implement surveillance or preventive strategies, avoiding the need for frequent post-operative endoscopic or radiographic examinations to detect recurrence early.
Solution Approach 2:
The patent replaces mechanical/invasive detection methods (endoscopy, radiographic techniques, histological examination) with a biochemical detection system using serological markers. This substitution eliminates the need for invasive procedures while maintaining recurrence prediction capability, thereby reducing patient burden while preserving detection accuracy.
2Measurement precision
If multiple serological and clinical markers are combined to predict recurrence, then prediction accuracy is improved, but test complexity increases
Solution Approach 1:
The patent segments the recurrence prediction process into distinct marker categories (ASCAs, anti-flagellin antibodies, pANCA, clinical markers) that can be measured independently. Each marker type targets specific aspects of disease pathology, and their combined results provide a comprehensive risk assessment. This segmentation allows for systematic evaluation while maintaining operational simplicity through standardized testing protocols.
3Ease of operation
If serological markers are used to predict recurrence, then patient burden is reduced, but prediction reliability may be compromised
Solution Approach 1:
The patent uses a composite marker panel combining multiple serological markers (ASCAs, anti-flagellin antibodies, pANCA) with clinical markers to predict recurrence. This composite approach leverages the complementary information from different marker types, where each marker targets different aspects of the disease process, thereby enhancing overall prediction reliability while maintaining the non-invasive nature of serological testing.
Data Source
AI summary
The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.